The pharmaceutical company Eugia US LLC has withdrawn a batch of its Methocarbamol Injections, used to treat musculoskeletal conditions, nationwide.
Injecting something that contains particles can cause irritation or swelling at the spot where the needle has gone in, the company said in its Food and Drug Administration (FDA) announcement.
This can “block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death,” the risk statement said.
The jabs are usually prescribed along with rest and physical therapy to treat conditions such as back pain, rheumatoid arthritis, gout and lupus, among others.
Azurity Pharmaceuticals said that a pharmacist in Nebraska reported opening a bottle of Zenzedi only to find tablets of Carbinoxamine Maleate, an antihistamine drug.
Azurity Pharmaceuticals warned in its release that “patients who take carbinoxamine instead of Zenzedi will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury.”
The original article contains 440 words, the summary contains 157 words. Saved 64%. I’m a bot and I’m open source!
This is the best summary I could come up with:
The pharmaceutical company Eugia US LLC has withdrawn a batch of its Methocarbamol Injections, used to treat musculoskeletal conditions, nationwide.
Injecting something that contains particles can cause irritation or swelling at the spot where the needle has gone in, the company said in its Food and Drug Administration (FDA) announcement.
This can “block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death,” the risk statement said.
The jabs are usually prescribed along with rest and physical therapy to treat conditions such as back pain, rheumatoid arthritis, gout and lupus, among others.
Azurity Pharmaceuticals said that a pharmacist in Nebraska reported opening a bottle of Zenzedi only to find tablets of Carbinoxamine Maleate, an antihistamine drug.
Azurity Pharmaceuticals warned in its release that “patients who take carbinoxamine instead of Zenzedi will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury.”
The original article contains 440 words, the summary contains 157 words. Saved 64%. I’m a bot and I’m open source!